OKYO Pharma to Showcase Urcosimod at Key Ophthalmology Forums
Event summary
- OKYO Pharma will present at Ophthalmology Futures European Forum on September 10, 2026, and ESCRS iNovation Day on September 11, 2026, in London.
- The company's lead asset, urcosimod, is in a global Phase 3 pivotal NEPTUNE trial for neuropathic corneal pain (NCP).
- Recent FDA Type D meeting provided positive feedback on urcosimod's regulatory and clinical path.
- OKYO Pharma reported a strengthened cash position in its Annual Report.
The big picture
OKYO Pharma's participation in these high-profile ophthalmology forums underscores its strategic focus on advancing urcosimod through late-stage clinical trials. The positive FDA feedback and strengthened cash position suggest the company is well-positioned to navigate the regulatory and financial challenges of bringing a novel therapy to market. The broader industry trend of increasing investment in ophthalmic innovations highlights the potential for significant value creation in this space.
What we're watching
- Clinical Progress
- The pace at which OKYO Pharma enrolls patients in the Phase 3 NEPTUNE trial will determine the timeline for urcosimod's potential approval.
- Regulatory Dynamics
- Whether the positive FDA feedback translates into smoother regulatory approvals for urcosimod in other markets.
- Investor Sentiment
- How investor reactions to the company's presentations and strengthened cash position impact its stock performance.
Related topics